27Apr
[Video] Six Things You Need to Know About Life Sciences M&A During and After COVID-19
While life sciences M&A activity soared to a new high in 2019, the uncertainty surrounding the pandemic has led to a slow down in deal making activity. However, as the crisis in the U.S. subsides and the U.S. economy stabilizes, we expect life...
By:
Arnall Golden Gregory LLP
Related
The OZ Digest is a regular update from the Polsinelli Opportunity Zones team. Our goal is to share e...
Read More >
Although employees won’t be able to receive the benefits of the new Massachusetts Paid Family and M...
Read More >
The Minnesota Legislature wrapped up its 2019 legislative session with a one-day special session las...
Read More >
Welcome to the latest edition of our Myanmar update for 2019. We have distilled the top news items i...
Read More >
As the pandemic drives companies to realign business strategies, look to your corporate treasury fun...
Read More >
Net operating losses (NOLs) of a corporation are often one of its most significant tax attributes an...
Read More >